Showing 6601-6610 of 6983 results for "".
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura™ for Skin Cancer Detectionhttps://practicaldermatology.com/news/20140623-verisante_technology_inc_partners_with_the_bc_cancer_foundation_to_showcase_aura_for_skin_cancer_detection/2459196/Verisante Technology, Inc. is partnering with the BC Cancer Foundation to showcase Verisante Aura™, a device for the detection of skin cancer. Verisante has placed an Aura™ at the Foundation's Provincial Office in Vancouver for display and educa
- South Beach Symposium Debuts New Host Hotelhttps://practicaldermatology.com/news/20140623-south_beach_symposium_debuts_new_host_hotel/2459198/The 13th annual meeting of the South Beach Symposium moves to the Fontainebleau Hotel in Miami Beach, February 12-16, 2015. Faculty for the event have been announced on the SBS website. There are non-overlapping CME tracks: the Mas
- Celsus Therapeutics Receives Ministry of Health of Israel Approval to Conduct Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/20140617-a_new_class_of_treatment_can_to_be_used_for_atopic_dermatitis/2459202/Celsus Therapeutics Plc received approval from Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients. The Company plans to conduct the study in five to six centers in Israel as well as Argentina. They plan to enroll 80 pediatric patient
- Spain's LETI Laboratories Launches Leading Atopic Skincare Line to U.S. Markethttps://practicaldermatology.com/news/20140617-spains_leti_laboratories_launches_leading_atopic_skincare_line_to_us_market/2459203/DermWORX Professional Skincare and LETI Laboratories, headquartered in Barcelona, Spain, will launch a series of top European dermatological products in the United States. The series includes: LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. heal
- Valeant Pharmaceuticals Announces Planned Management Departurehttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_announces_planned_management_departure/2459206/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport ow
- TruInject Injector Training System Receives Approval of Its Patenthttps://practicaldermatology.com/news/20140613-truinject_injector_training_system_receives_approval_of_its_patent/2459207/One of the key patent applications of TruInject Medical Corporation has been allowed by the US Patent Office. The patent is expected to issue shortly. The patent is for a cosmetic and therapeutic injector training system and is one of many pate
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- Allergan: Business As Usual Following New Valeant Offerhttps://practicaldermatology.com/news/20140606-allergan_business_as_usual_following_new_valeant_offer/2459215/At Allergan, executives say it is business as usual, even as the board reviews a hefty new offer from Valeant. Valeant last Friday increased its offer to Allergan by $14 per share, “subject to prompt good-faith discussions on a merger agreement.” The new bid values Allergan at about $180 a share and